BusinessPetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration SubmissionBy Nasdaq OMXOct 13, 2016, 12:02 PM UTC
BusinessPetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate UpdateBy Nasdaq OMXOct 10, 2016, 12:00 PM UTC
BusinessGalectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic SteatohepatitisBy Nasdaq OMXOct 7, 2016, 12:30 PM UTC
BusinessCell Design Labs Announces Peer-Reviewed Publication Validating Ability to Program Immune Cells to Treat Cancer and Autoimmune DiseaseBy Nasdaq OMXSep 29, 2016, 4:00 PM UTC
BusinessPetLife Pharmaceuticals Explores Product Expansion with Strategic Partner(s); Successfully Presents at Two Financial Conferences in SeptemberBy Nasdaq OMXSep 28, 2016, 2:30 PM UTC
BusinessGalectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced FibrosisBy Nasdaq OMXSep 27, 2016, 8:15 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessMD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple CancersBy Nasdaq OMXSep 26, 2016, 11:30 AM UTC
